Total Payments
$2,896
2024 Payments
$226.56
Companies
17
Transactions
109
Medicare Patients
2,249
Medicare Billing
$226,967
Payment Breakdown by Category
Food & Beverage$2,896 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,896 | 109 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Tepha Inc | $1,549 | 22 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $340.60 | 24 | $0 (2024) |
| ABBVIE INC. | $248.75 | 18 | $0 (2022) |
| Grifols USA, LLC | $130.60 | 9 | $0 (2021) |
| Abbott Laboratories | $125.00 | 1 | $0 (2024) |
| Amarin Pharma Inc. | $123.08 | 9 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $94.92 | 6 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $74.55 | 5 | $0 (2023) |
| Allergan, Inc. | $74.01 | 6 | $0 (2020) |
| Lilly USA, LLC | $29.19 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $226.56 | 8 | Abbott Laboratories ($125.00) |
| 2023 | $180.60 | 12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($105.46) |
| 2022 | $283.50 | 19 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($105.71) |
| 2021 | $178.03 | 13 | Amarin Pharma Inc. ($68.32) |
| 2020 | $162.51 | 12 | AbbVie Inc. ($80.19) |
| 2019 | $1,137 | 24 | Tepha Inc ($989.10) |
| 2018 | $637.36 | 15 | Tepha Inc ($559.60) |
| 2017 | $90.47 | 6 | Grifols USA, LLC ($28.21) |
All Payment Transactions
109 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Gastroenterology | ||||||
| 10/10/2024 | Abbott Laboratories | ETERNA (Device) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neuromodulation | ||||||
| 09/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: Gastroenterology | ||||||
| 06/26/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Gastroenterology | ||||||
| 03/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: Gastroenterology | ||||||
| 02/21/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: Gastroenterology | ||||||
| 01/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Gastroenterology | ||||||
| 01/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: Gastroenterology | ||||||
| 10/11/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: Gastroenterology | ||||||
| 10/09/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: DIABETES | ||||||
| 10/02/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Gastroenterology | ||||||
| 06/21/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Gastroenterology | ||||||
| 06/13/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/09/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Gastroenterology | ||||||
| 04/26/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Gastroenterology | ||||||
| 04/26/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Diabetes | ||||||
| 04/18/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/01/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Gastroenterology | ||||||
| 02/01/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Diabetes | ||||||
| 01/26/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Gastroenterology | ||||||
| 12/30/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Gastroenterology | ||||||
| 12/10/2022 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $19.96 | General |
| Category: BIOLOGIC | ||||||
| 10/12/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/06/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Gastroenterology | ||||||
| 10/05/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 526 | 1,053 | $91,212 | $51,235 |
| 2022 | 10 | 521 | 1,208 | $104,364 | $55,360 |
| 2021 | 10 | 615 | 1,399 | $119,283 | $63,073 |
| 2020 | 8 | 587 | 1,297 | $107,202 | $57,299 |
Total Patients
2,249
Total Services
4,957
Medicare Billing
$226,967
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 113 | 362 | $43,600 | $27,032 | 62.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 56 | 56 | $9,330 | $7,939 | 85.1% |
| 36410 | Insertion of needle into vein (3 years or older) | Office | 2023 | 120 | 344 | $9,845 | $4,754 | 48.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 50 | $12,632 | $3,382 | 26.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $5,540 | $3,109 | 56.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 50 | 51 | $2,030 | $1,728 | 85.1% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 51 | 52 | $1,560 | $1,137 | 72.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 13 | 13 | $3,040 | $904.41 | 29.8% |
| 90471 | Administration of vaccine | Office | 2023 | 21 | 43 | $1,630 | $730.80 | 44.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 37 | 43 | $1,710 | $514.40 | 30.1% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 11 | 14 | $295.00 | $5.87 | 2.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 111 | 410 | $40,642 | $26,921 | 66.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 64 | 64 | $10,160 | $9,412 | 92.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 47 | 137 | $34,122 | $8,307 | 24.3% |
| 36410 | Insertion of needle into vein (3 years or older) | Office | 2022 | 119 | 393 | $10,370 | $5,434 | 52.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 52 | 52 | $2,000 | $1,718 | 85.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $2,360 | $1,529 | 64.8% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 55 | 55 | $1,920 | $1,160 | 60.4% |
| 90471 | Administration of vaccine | Office | 2022 | 24 | 42 | $1,330 | $574.79 | 43.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 27 | 29 | $1,160 | $298.18 | 25.7% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2022 | 11 | 15 | $300.00 | $6.52 | 2.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 124 | 487 | $44,118 | $30,444 | 69.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 65 | 65 | $9,773 | $9,659 | 98.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 45 | 131 | $33,247 | $8,182 | 24.6% |
| 36410 | Insertion of needle into vein, patient 3 years or older | Office | 2021 | 132 | 451 | $11,570 | $6,179 | 53.4% |
About Dr. John Kim, M.D
Dr. John Kim, M.D is a Geriatric Medicine healthcare provider based in Fort Lee, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659359263.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Kim, M.D has received a total of $2,896 in payments from pharmaceutical and medical device companies, with $226.56 received in 2024. These payments were reported across 109 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($2,896).
As a Medicare-enrolled provider, Kim has provided services to 2,249 Medicare beneficiaries, totaling 4,957 services with total Medicare billing of $226,967. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Other Specialties Internal Medicine
- Location Fort Lee, NJ
- Active Since 01/04/2006
- Last Updated 07/21/2022
- Taxonomy Code 207RG0300X
- Entity Type Individual
- NPI Number 1659359263
Products in Payments
- GalaFLEX (Device) $1,549
- XIFAXAN (Drug) $340.60
- ETERNA (Device) $125.00
- Vascepa (Drug) $123.08
- Creon (Drug) $112.69
- Prolastin-C Liquid (Biological) $102.39
- JARDIANCE (Drug) $67.71
- CREON (Drug) $66.41
- TRADJENTA (Drug) $56.40
- FARXIGA (Drug) $44.86
- LINZESS (Drug) $39.83
- BYSTOLIC (Drug) $33.52
- ZENPEP (Drug) $31.53
- RINVOQ (Biological) $29.82
- Prolastin-C (Biological) $28.21
- RUCONEST (Biological) $19.96
- CINRYZE (Drug) $17.37
- FASENRA (Drug) $15.08
- ELIQUIS (Drug) $14.98
- BREZTRI (Drug) $14.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.